title: Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy.
abstract: Innate lymphoid cells (ILCs) play an important role in immunity, inflammation, and tissue remodeling and their dysregulation is implicated in autoimmune and inflammatory disorders. We analyzed the impact of daclizumab, a humanized monoclonal anti-CD25 antibody, on circulating natural killer (NK) cells and ILCs in a cohort of multiple sclerosis patients. An increase in CD56(bright) NK cells and CD56(hi)CD16(intermediate) transitional NK cells was observed. No significant change in total ILCs or major ILC subpopulations was observed. These results refine our understanding of the impact of daclizumab on innate lymphoid cell populations.
authors.affiliation: Biogen, Inc., 115 Broadway, Cambridge, MA 02142, United States. Electronic address: geoff.gillard@biogen.com.
authors.forename: Geoffrey O
authors.initials: GO
authors.lastname: Gillard
authors.affiliation: Celgene Avilomics Research, 200 Cambridge Park Dr., Cambridge, MA 02140, United States.
authors.forename: Steven A
authors.initials: SA
authors.lastname: Saenz
authors.affiliation: Juno Therapeutics, 307 Westlake Ave N, Suite 300; Seattle, WA 98109, United States.
authors.forename: David J
authors.initials: DJ
authors.lastname: Huss
authors.affiliation: Juno Therapeutics, 307 Westlake Ave N, Suite 300; Seattle, WA 98109, United States.
authors.forename: Jason D
authors.initials: JD
authors.lastname: Fontenot
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D015703:Antigens, CD / Q000378:metabolism; D015331:Cohort Studies; D000077561:Daclizumab; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab
keywords: Daclizumab; ILC; Innate lymphoid cell; NK; Natural killer